Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,597,999
  • Shares Outstanding, K 45,540
  • Annual Sales, $ 29,540 K
  • Annual Income, $ -145,440 K
  • 60-Month Beta 1.15
  • Price/Sales 57.46
  • Price/Cash Flow N/A
  • Price/Book 3.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.87
  • Number of Estimates 4
  • High Estimate -0.72
  • Low Estimate -0.95
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +2.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.00 +6.33%
on 06/15/20
41.29 -15.02%
on 06/23/20
-2.54 (-6.75%)
since 06/09/20
3-Month
32.77 +7.08%
on 05/12/20
41.49 -15.43%
on 04/20/20
-2.69 (-7.12%)
since 04/09/20
52-Week
20.33 +72.60%
on 03/18/20
52.75 -33.48%
on 01/22/20
+10.34 (+41.78%)
since 07/09/19

Most Recent Stories

More News
Zymeworks Corporate Update Webcast and Conference Call Summary

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments...

ZYME : 35.09 (-5.87%)
Zymeworks Announces New Multispecific Antibody Collaboration with Merck

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and...

MRK : 76.69 (-1.58%)
ZYME : 35.09 (-5.87%)
Zymeworks Announces Corporate Update Webcast and Conference Call

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a webcast and conference call to discuss progress on its...

ZYME : 35.09 (-5.87%)
Zymeworks (ZYME) Catches Eye: Stock Jumps 7.7%

Zymeworks (ZYME) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ZYME : 35.09 (-5.87%)
AKCA : 13.29 (-4.35%)
Moving Average Crossover Alert: Zymeworks

Zymeworks Inc. (ZYME) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

ZYME : 35.09 (-5.87%)
Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare...

ZYME : 35.09 (-5.87%)
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered...

ZYME : 35.09 (-5.87%)
Zymeworks Inc (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 35.09 (-5.87%)
Zymeworks Reports 2020 First Quarter Financial Results

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.

ZYME : 35.09 (-5.87%)
Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm...

ZYME : 35.09 (-5.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ZYME with:

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 38.26
1st Resistance Point 36.67
Last Price 35.09
1st Support Level 33.55
2nd Support Level 32.02

See More

52-Week High 52.75
Fibonacci 61.8% 40.37
Fibonacci 50% 36.54
Last Price 35.09
Fibonacci 38.2% 32.71
52-Week Low 20.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar